DK302587D0 - Praeparat til kontrolleret frigivelse af carbidopa og levodopa - Google Patents

Praeparat til kontrolleret frigivelse af carbidopa og levodopa

Info

Publication number
DK302587D0
DK302587D0 DK302587A DK302587A DK302587D0 DK 302587 D0 DK302587 D0 DK 302587D0 DK 302587 A DK302587 A DK 302587A DK 302587 A DK302587 A DK 302587A DK 302587 D0 DK302587 D0 DK 302587D0
Authority
DK
Denmark
Prior art keywords
carbidopa
levodopa
controlled release
preparation
polymer
Prior art date
Application number
DK302587A
Other languages
English (en)
Other versions
DK170514B1 (da
DK302587A (da
Inventor
Robert E Dempski
Edward C Scholtz
Donald W Nibbelink
Scott A Reines
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK302587(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK302587D0 publication Critical patent/DK302587D0/da
Publication of DK302587A publication Critical patent/DK302587A/da
Application granted granted Critical
Publication of DK170514B1 publication Critical patent/DK170514B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK302587A 1986-06-16 1987-06-15 Præparat til reguleret frigivelse af carbidopa og levodopa DK170514B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16
US87498886 1986-06-16

Publications (3)

Publication Number Publication Date
DK302587D0 true DK302587D0 (da) 1987-06-15
DK302587A DK302587A (da) 1987-12-17
DK170514B1 DK170514B1 (da) 1995-10-09

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK302587A DK170514B1 (da) 1986-06-16 1987-06-15 Præparat til reguleret frigivelse af carbidopa og levodopa

Country Status (17)

Country Link
EP (1) EP0253490B1 (da)
JP (1) JPS6354319A (da)
KR (1) KR950002882B1 (da)
AT (1) ATE58473T1 (da)
AU (1) AU597670B2 (da)
CY (1) CY1578A (da)
DE (1) DE3766308D1 (da)
DK (1) DK170514B1 (da)
ES (1) ES2018548B3 (da)
GR (1) GR3001102T3 (da)
HK (1) HK56191A (da)
IE (1) IE60508B1 (da)
IL (1) IL82823A (da)
NZ (1) NZ220599A (da)
PT (1) PT85049B (da)
SG (1) SG52191G (da)
ZA (1) ZA874233B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1946780B1 (en) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2978418A1 (en) * 2013-03-28 2016-02-03 OmniActive Health Technologies Limited Neuroprotective effect of carotenoids in brain
EP3054929B1 (en) 2013-10-07 2020-08-05 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
DE3271647D1 (en) * 1981-07-08 1986-07-17 Key Pharma Polymeric diffusion matrix containing propranolol
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK170514B1 (da) 1995-10-09
PT85049A (en) 1987-07-01
EP0253490A1 (en) 1988-01-20
DE3766308D1 (de) 1991-01-03
JPS6354319A (ja) 1988-03-08
KR880000086A (ko) 1988-03-23
DK302587A (da) 1987-12-17
EP0253490B1 (en) 1990-11-22
KR950002882B1 (ko) 1995-03-28
ATE58473T1 (de) 1990-12-15
IE60508B1 (en) 1994-07-27
IL82823A (en) 1991-03-10
IL82823A0 (en) 1987-12-20
AU7422887A (en) 1987-12-17
HK56191A (en) 1991-07-26
SG52191G (en) 1991-08-23
AU597670B2 (en) 1990-06-07
GR3001102T3 (en) 1992-05-12
ZA874233B (en) 1987-12-14
PT85049B (pt) 1990-03-08
IE871559L (en) 1987-12-16
ES2018548B3 (es) 1991-04-16
JPH0445B2 (da) 1992-01-06
NZ220599A (en) 1990-10-26
CY1578A (en) 1991-12-20

Similar Documents

Publication Publication Date Title
DK685888D0 (da) Praeparat til kontrolleret afgivelse af carbidopa og levodopa
DK302587A (da) Praeparat til kontrolleret frigivelse af carbidopa og levodopa
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE69414502D1 (de) Medizinische Vorrichtung zur Verabreichung von Aktivsubstanzen oder Arzneistoffen in sehr niedriger Dosis, insbesondere von homöopatischen Arzneistoffen
ATE77962T1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
DK0388306T3 (da) Farmaceutisk præparat til behandling af smerte knyttet til herpes zoster og postherpetisk neuralgi ved topisk påføring af l
DK164482C (da) Middel i form af folier til transdermal applikation af stoffer, der er virksomme som laegemidler, samt fremgangsmaade til fremstilling heraf
ATE153538T1 (de) Transdermale therapeutische zubereitungen
DE3879853D1 (de) Klebstoffzusammensetzung, zusammensetzung mit kontrollierter wirkstofffreisetzung und system zur transdermalen anwendung von arzneien.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
YU49390A (sh) Postupak za izradu transdermalnog terapijskog sistema sa stupnjevitim otpuštanjem aktivne materije
FI104151B1 (fi) Laite vaikuttavan aineen luovuttamiseksi ohjatusti

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired